drugset / Trial / NCT03428945
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
Phase 2
Terminated
273 enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Juvenile Diabetes Research Foundation · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of T1D.
Timeline
- Start
- 2018-08-15
- Primary completion
- 2022-10-27
- Completion
- 2022-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | — | Oral |